

ForPatients

by Roche

Huntington Disease (HD)

Study to Measure Cerebrospinal Fluid Mutant Huntingtin Protein in Participants With Early Manifest Stage I or Stage II Huntington's Disease

Trial Status
Completed

Trial Runs In
4 Countries

Trial Identifier
NCT03664804 BN40422

The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.

Trial Summary:

The study is designed as a multi-site, prospective, 15-month longitudinal, cohort study measuring CSF mHTT in participants with early manifest Stage I or Stage II Huntington's Disease (HD).

Hoffmann-La Roche
Sponsor

Phase

NCT03664804 BN40422
Trial Identifiers

Eligibility Criteria:

Gender
All

Age
>= 25 Years & <= 65 Years

Healthy Volunteers
No
